DK2566507T3 - Biokonjugatvacciner med kapselformige grampositive bakterier - Google Patents

Biokonjugatvacciner med kapselformige grampositive bakterier

Info

Publication number
DK2566507T3
DK2566507T3 DK11724567.0T DK11724567T DK2566507T3 DK 2566507 T3 DK2566507 T3 DK 2566507T3 DK 11724567 T DK11724567 T DK 11724567T DK 2566507 T3 DK2566507 T3 DK 2566507T3
Authority
DK
Denmark
Prior art keywords
gram
bioconjugate
positive
polysaccharides
directed
Prior art date
Application number
DK11724567.0T
Other languages
English (en)
Inventor
Michael Wacker
Michael Kowarik
Michael Wetter
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Application granted granted Critical
Publication of DK2566507T3 publication Critical patent/DK2566507T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DK11724567.0T 2010-05-06 2011-05-04 Biokonjugatvacciner med kapselformige grampositive bakterier DK2566507T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33217010P 2010-05-06 2010-05-06
PCT/EP2011/057111 WO2011138361A1 (en) 2010-05-06 2011-05-04 Capsular gram-positive bacteria bioconjugate vaccines

Publications (1)

Publication Number Publication Date
DK2566507T3 true DK2566507T3 (da) 2018-01-29

Family

ID=44902091

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11724567.0T DK2566507T3 (da) 2010-05-06 2011-05-04 Biokonjugatvacciner med kapselformige grampositive bakterier

Country Status (20)

Country Link
US (3) US8871491B2 (da)
EP (2) EP3281639B1 (da)
JP (2) JP6339366B2 (da)
KR (2) KR101916290B1 (da)
CN (1) CN103079591B (da)
AU (2) AU2011249839B2 (da)
CA (1) CA2798381C (da)
CY (1) CY1119895T1 (da)
DK (1) DK2566507T3 (da)
ES (2) ES2657588T3 (da)
HR (1) HRP20180064T1 (da)
HU (1) HUE037956T2 (da)
IL (1) IL222711B (da)
LT (1) LT2566507T (da)
NO (1) NO2566507T3 (da)
PL (1) PL2566507T3 (da)
PT (1) PT2566507T (da)
SG (1) SG185433A1 (da)
SI (1) SI2566507T1 (da)
WO (1) WO2011138361A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL163806A0 (en) * 2002-03-07 2005-12-18 Eidgenoess Tech Hochschule System and method for the production of recombinant glycosylated proteins in a prokaryotic host
HUE039413T2 (hu) 2008-02-20 2018-12-28 Glaxosmithkline Biologicals Sa Prokarióta sejtekbõl származó rekombináns N-glikozilált fehérjékbõl készített biokonjugátumok
LT2501406T (lt) 2009-11-19 2018-03-26 Glaxosmithkline Biologicals S.A. Biosintetinė sistema sukurianti imunogeninius polisacharidus prokariotinėse gardelėse
CA2894795A1 (en) * 2012-04-27 2013-10-31 The Governors Of The University Of Alberta Glycoengineered outer membrane vesicles and use thereof as vaccines
US9777076B2 (en) 2012-07-16 2017-10-03 Pfizer Inc. Saccharides and uses thereof
US9962436B2 (en) 2012-07-26 2018-05-08 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Multimeric fusion protein vaccine and immunotherapeutic
BR112015008052A2 (pt) 2012-10-12 2017-11-28 Glycovaxyn Ag célula hospedeira, métodos para produzir um glicoconjugado e para produzir uma proteína n-glicosilada, e, glicoconjugado
CA3125293A1 (en) 2012-11-07 2014-05-15 Glaxosmithkline Biologicals Sa Production of recombinant vaccine in e. coli by enzymatic conjugation
EP2946010B1 (en) 2013-01-18 2018-08-29 London School of Hygiene and Tropical Medicine Glycosylation method
GB201301085D0 (en) 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
CN106062203B (zh) * 2013-10-11 2020-08-07 葛兰素史密丝克莱恩生物有限公司 宿主细胞修饰的方法
EP3076998A1 (en) 2013-12-04 2016-10-12 Glycovaxyn AG Prevention of staphylococcus aureus infections by glycoprotein vaccines synthesized in escherichia coli
CN106794237B (zh) * 2014-04-17 2022-04-12 葛兰素史密丝克莱恩生物有限公司 经修饰的宿主细胞及其用途
ES2793023T3 (es) 2014-08-08 2020-11-12 Glaxosmithkline Biologicals Sa Células huésped modificadas y oligosacáridos híbridos para su uso en producción de bioconjugados
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016073773A1 (en) * 2014-11-05 2016-05-12 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
US10500261B2 (en) 2014-11-05 2019-12-10 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
MX2017008817A (es) 2014-12-30 2017-10-24 Glaxosmithkline Biologicals Sa Composiciones y metodos para la glicosilacion de proteinas.
CA2990312A1 (en) * 2015-07-01 2017-01-05 Glaxosmithkline Biologicals S.A. Immunogenic compositions
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201610599D0 (en) * 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
GB201712678D0 (en) 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
CN108330142B (zh) * 2018-02-09 2021-09-17 河北科技师范学院 一种具有免疫保护作用的美人鱼发光杆菌溶血素Hlych蛋白
GB201802339D0 (en) 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CN109400704B (zh) * 2018-11-14 2020-07-21 珠海泰诺麦博生物技术有限公司 一种抗金黄色葡萄球菌α-溶血素的抗体及其应用
EP3894431A2 (en) * 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Modified carrier proteins for o-linked glycosylation
CN113646438A (zh) * 2019-01-11 2021-11-12 西北大学 在原核生物细胞裂解物中合成生物缀合物疫苗
EP3757217A1 (en) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
EP3770269A1 (en) * 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
PL4010467T3 (pl) 2019-08-09 2024-08-05 Glaxosmithkline Biologicals Sa Zmutowane enzymy oligosacharylotransferazy pglb
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CN112575041B (zh) * 2019-09-30 2022-12-13 江南大学 一种混合碳源高效发酵生产phb的工程菌及其应用
BR112022024267A2 (pt) * 2020-06-25 2023-01-17 Glaxosmithkline Biologicals Sa Vacina
CN114085255B (zh) * 2020-08-24 2023-08-29 山东大学 一种苏黎世克罗诺杆菌5型脂多糖o-抗原寡糖片段及其制备方法与应用
WO2022171679A2 (en) 2021-02-11 2022-08-18 Glaxosmithkline Biologicals Sa Protein
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
WO2024002331A1 (en) * 2022-06-30 2024-01-04 Shanghai Yuguan Biotech Co., Ltd. A live bacteria strain with reduced capsules
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
CN117771264B (zh) * 2023-11-27 2024-06-25 山东省农业科学院畜牧兽医研究所 circHIF1α在制备抵御细菌感染的新型疫苗中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1900A (en) 1840-12-14 Machine for extracting stumps
EP0170204B1 (de) 1984-08-01 1991-09-25 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Neue genetische Sequenzen, die durch sie codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
JPH09501044A (ja) 1993-05-14 1997-02-04 ジ・アップジョン・カンパニー ＵＤＰ−ＧＡＬＮＡｃ：ポリペプチド、Ｎ−アセチルガラクトサミニルトランスフェラーゼをコードするクローン化されたＤＮＡ
US6503744B1 (en) 1999-02-01 2003-01-07 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
JP2003524395A (ja) 1999-03-02 2003-08-19 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 細胞内シアリル化経路の操作
EP1285072A2 (en) 2000-05-12 2003-02-26 Neose Technologies, Inc. In vitro fucosylation recombinant glycopeptides
AU7765801A (en) 2000-06-30 2002-01-08 Flanders Interuniversity Inst Protein glycosylation modification in pichia pastoris
JP4727927B2 (ja) 2002-03-07 2011-07-20 アイトゲネシシェ・テッヒニシェ・ホーホシューレ・チューリッヒ 原核宿主における組換えグリコシル化タンパク質産生のためのシステムおよび方法
IL163806A0 (en) 2002-03-07 2005-12-18 Eidgenoess Tech Hochschule System and method for the production of recombinant glycosylated proteins in a prokaryotic host
BR0312896A (pt) 2002-08-01 2005-06-14 Ca Nat Research Council Glicanos e glicopeptìdeos de campylobacter
US8071113B2 (en) 2004-05-24 2011-12-06 The United States Of America As Represented By The Department Of Health And Human Services Live, oral vaccine for protection against Shigella dysenteriae serotype 1
WO2006119987A2 (en) * 2005-05-11 2006-11-16 ETH Zürich Recombinant n-glycosylated proteins from procaryotic cells
AU2007233705B2 (en) 2006-03-30 2010-12-23 Glaxosmithkline Biologicals S.A. Immunogenic composition
JP5647899B2 (ja) * 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
HUE039413T2 (hu) 2008-02-20 2018-12-28 Glaxosmithkline Biologicals Sa Prokarióta sejtekbõl származó rekombináns N-glikozilált fehérjékbõl készített biokonjugátumok

Also Published As

Publication number Publication date
LT2566507T (lt) 2018-02-12
IL222711B (en) 2018-10-31
CN103079591B (zh) 2017-07-28
ES2844596T3 (es) 2021-07-22
US20170128559A1 (en) 2017-05-11
US20110274720A1 (en) 2011-11-10
JP2013524844A (ja) 2013-06-20
AU2016208265A1 (en) 2016-08-11
IL222711A0 (en) 2012-12-31
HRP20180064T1 (hr) 2018-02-23
US20150010592A1 (en) 2015-01-08
KR101916290B1 (ko) 2018-11-09
JP6435583B2 (ja) 2018-12-12
HUE037956T2 (hu) 2018-09-28
ES2657588T3 (es) 2018-03-06
KR20180021219A (ko) 2018-02-28
EP2566507B1 (en) 2017-11-22
US8871491B2 (en) 2014-10-28
EP3281639A1 (en) 2018-02-14
PT2566507T (pt) 2018-02-06
US9585950B2 (en) 2017-03-07
EP2566507A1 (en) 2013-03-13
SG185433A1 (en) 2012-12-28
KR20130063510A (ko) 2013-06-14
JP6339366B2 (ja) 2018-06-06
CA2798381C (en) 2020-10-06
SI2566507T1 (en) 2018-04-30
JP2017036303A (ja) 2017-02-16
CA2798381A1 (en) 2011-11-10
NO2566507T3 (da) 2018-04-21
AU2011249839A1 (en) 2012-11-29
US10307473B2 (en) 2019-06-04
AU2011249839B2 (en) 2016-05-26
WO2011138361A1 (en) 2011-11-10
CN103079591A (zh) 2013-05-01
EP3281639B1 (en) 2020-11-11
PL2566507T3 (pl) 2018-05-30
CY1119895T1 (el) 2018-06-27

Similar Documents

Publication Publication Date Title
DK2566507T3 (da) Biokonjugatvacciner med kapselformige grampositive bakterier
NZ723328A (en) Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
MX2011011505A (es) Vacuna neumococica y usos de la misma.
CA2830786C (en) Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a
PH12014501835A1 (en) Novel adjuvant compositions
WO2010033274A3 (en) Nanoemulsion adjuvants
IN2014CN04187A (da)
IN2012DN01898A (da)
WO2013006055A8 (en) A process for detergent-free production of outer membrane vesicles of a gram-negative bacterium
NZ585777A (en) Compositions and methods of enhancing immune responses to eimeria
PH12016500360A1 (en) A bacterial vaccine and methods for manufacture thereof
PH12014502855A1 (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
WO2012097185A3 (en) Omv vaccine against burkholderia infections
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
WO2015051371A3 (en) Haemophilus parasuis vaccine serovar type four
EA200701130A1 (ru) Электропорация микобактерии и сверхэкспрессия антигенов микобактерий
WO2011112906A3 (en) Novel immunogens and methods for discovery and screening thereof
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
WO2008127450A3 (en) Linear expression cassette vaccines
WO2013084070A3 (en) Salmonella vaccine proteins
WO2013049535A3 (en) Influenza vaccine
WO2011128892A3 (en) Modified forms of pneumococcal surface immunogenic protein b (psipb)
MY158116A (en) Combination vaccine against streptococcus
GB201021096D0 (en) Vaccine
MY177159A (en) Attenuated bacteria for use in a vaccine